Publications by authors named "Lee Phebus"

Claim this Profile
E
Efficiency gains in tracer identification for nuclear imaging: can in vivo LC-MS/MS evaluation of small molecules screen for successful PET tracers?
Elizabeth M Joshi, Anne Need, John Schaus, Zhaogen Chen, Dana Benesh, Lee Phebus

ACS Chem Neurosci· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor.
Nicolas Dreyfus, Jason K Myers, Valentina O Badescu, Oscar de Frutos, Maria Luz de la Puente, Lee A Phebus

ACS Med Chem Lett· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3-Phenyl-5-isothiazole carboxamides with potent mGluR1 antagonist activity.
Matthew J Fisher, Ryan T Backer, Vanessa N Barth, Kim E Garbison, Joseph M Gruber, Lee Phebus

Bioorg Med Chem Lett· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan.
David L Nelson, Lee A Phebus, Kirk W Johnson, David B Wainscott, Marlene L Cohen

Cephalalgia· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography.
Garth E Terry, Jussi Hirvonen, Jeih-San Liow, Nicholas Seneca, Johannes T Tauscher, Lee Phebus

Eur J Nucl Med Mol Imaging· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands.
Garth E Terry, Jussi Hirvonen, Jeih-San Liow, Sami S Zoghbi, Robert Gladding, Lee Phebus

J Nucl Med· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand.
Garth E Terry, Jeih-San Liow, Sami S Zoghbi, Jussi Hirvonen, Amanda G Farris, Lee Phebus

Neuroimage· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas.
Kenneth W Perry, Julie F Falcone, Matthew J Fell, John W Ryder, Hong Yu, Lee A Phebus

Neuropharmacology· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging.
Sean R Donohue, Joseph H Krushinski, Victor W Pike, Eyassu Chernet, Lee Phebus

J Med Chem· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents.
Garth Terry, Jeih-San Liow, Eyassu Chernet, Sami S Zoghbi, Lee Phebus

Neuroimage· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PET radioligand [11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain.
Fumihiko Yasuno, Amira K Brown, Sami S Zoghbi, Joseph H Krushinski, Eyassu Chernet, Lee A Phebus

Neuropsychopharmacology· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously.
Anne B Need, Jamie H McKinzie, Charles H Mitch, Michael A Statnick, Lee A Phebus

Life Sci· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and SAR studies of novel GlyT1 inhibitors.
Magnus W Walter, Beth J Hoffman, Kimberly Gordon, Kirk Johnson, Patrick Love, Lee Phebus

Bioorg Med Chem Lett· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo.
Brianne Weiss, Andrew Alt, Ann Marie Ogden, Mary Gates, Donna K Dieckman, Lee A Phebus

J Pharmacol Exp Ther· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer.
Vanessa N Barth, Eyassu Chernet, Laura J Martin, Anne B Need, Karen S Rash, Lee A Phebus

Life Sci· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications.
Eleni T Tzavara, Dominic L Li, Larissa Moutsimilli, Tiziana Bisogno, Vincenzo Di Marzo, Lee A Phebus

Biol Psychiatry· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats.
Anne B Need, Richard J Davis, Jesline T Alexander-Chacko, Brian Eastwood, Eyassu Chernet, Lee A Phebus

Psychopharmacology (Berl)· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples.
Eyassu Chernet, Laura J Martin, Dominic Li, Anne B Need, Vanessa N Barth, Lee A Phebus

Life Sci· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder.
Matthew A Seager, Vanessa N Barth, Lee A Phebus, Kurt Rasmussen

Psychopharmacology (Berl)· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity.
Matthew A Seager, Keith D Huff, Vanessa N Barth, Lee A Phebus, Kurt Rasmussen

Biol Psychiatry· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo characterization of changes in glycine levels induced by GlyT1 inhibitors.
Kirk W Johnson, Amy Clemens-Smith, George Nomikos, Richard Davis, Lee Phebus

Ann N Y Acad Sci· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel potent 5-HT(1F) receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides.
Sandra A Filla, Brian M Mathes, Kirk W Johnson, Lee A Phebus, Marlene L Cohen

J Med Chem· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine.
Sandra A Filla, Mark A Winter, Kirk W Johnson, David Bleakman, Michael G Bell, Lee A Phebus

J Med Chem· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex.
Frank P Bymaster, Wei Zhang, Petra A Carter, Janice Shaw, Eyassu Chernet, Lee Phebus

Psychopharmacology (Berl)· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis